Bio-Thera Reports Clinical Data for Lung Cancer Treatment at ESMO 2026

Bio-Thera Solutions disclosed clinical data at the 2026 ESMO conference regarding the combination of BAT8008, a TROP2-targeting antibody-drug conjugate, and BAT1308, an anti-PD-1 monoclonal antibody. The presentation focused on the efficacy and safety profile of the treatment regimen when applied as a first-line therapy for patients with advanced non-small cell lung cancer.

The development of TROP2-targeted agents is a competitive area within oncology, with many biopharmaceutical companies seeking to improve outcomes compared to existing immunotherapy benchmarks. Bio-Thera's data release aims to demonstrate the viability of combining its proprietary ADC with its PD-1 inhibitor to address gaps in treatment for advanced-stage patients.

The company stated that the findings provide necessary evidence to advance the clinical trial program. Further data will be required to confirm the long-term clinical benefits and safety profile of the combined regimen before moving toward late-stage development milestones.